VALENCIA, Calif. — SetPoint Medical has raised $140 million in private financing to support the commercialization of its neuroimmune modulation therapy for moderate-to-severe rheumatoid arthritis and to advance its pipeline for other autoimmune diseases.
The funding includes $25 million from the second tranche of its Series C round and $115 million from its Series D round, co-led by Elevage Medical Technologies and Ally Bridge Group. New investors include Northwell Health, SPRIG Equity, and an undisclosed strategic investor, while returning backers such as Norwest, New Enterprise Associates, Viking Global Investors, and Abbott also participated.
Josh Makower, M.D., joined SetPoint’s board as Elevage’s representative, alongside Kevin Reilly of Ally Bridge Group. The company also appointed two executives ahead of its planned U.S. market launch: Erik Styacich as vice president of sales and Spencer Bailey as vice president of market access and reimbursement.
SetPoint plans to introduce its SetPoint System — described as the first neuroimmune modulation therapy for adults with moderate-to-severe rheumatoid arthritis — in select U.S. markets this year, with broader national expansion in 2026.
“We are pleased to share these strategic milestones underpinning our commitment to a successful and seamless market launch for the SetPoint System,” said Murthy V. Simhambhatla, Ph.D., the company’s CEO. “We are thrilled to welcome an outstanding group of new investors to our exceptional syndicate.”
